Feb 4, 2020: Vituro Health announce that it, in partnership with Choice Diagnostic Imaging, successfully completed the first three TULSA-PRO® treatments to ablate prostate tissue in patients recently diagnosed with Prostate Cancer on Jan.11th and Jan. 25th, 2020 in Sarasota, FL.
The procedures were performed by the Vituro Health’s Medical Director, Dr. Stephen Scionti, one of the nation’s leading authorities in non-invasive ablative therapies for the treatment of the prostate cancer.
The technology’s developer, thoughtful Medical Corp., received 510(k) clearance from the U.S. FDA to the market TULSA-PRO® for ablation of prostate tissue in August 2019.
TULSA-PRO® is the transurethral prostate tissue ablation system that combines real-time Magnetic Resonance Imaging (“MRI”) with the robotically-driven directional thermal ultrasound and closed-loop temperature feedback control software in order to deliver predictable physician-prescribed ablation of whole-gland or biased prostate tissue.
The TULSA-PRO® system is designed to offer customizable and predictable, incision-free and radiation-free prostate ablation while vigorously protecting the urethra and rectum with water cooling to preserve men’s functional abilities.
Vituro Health began looking at this technology for about 3 years ago, recognizing the value this treatment could bring to the market.
Patients are now being screened and treatment dates are satisfying for this exciting new technology.
https://fda.einnews.com/pr_news/508816555/vituro-health-successfully-completes-first-tulsa-pro-cases-in-the-united-states-following-fda-510-k-clearance
